Adamas Appoints New Chief Financial Officer
28 June 2017 - 11:00PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the
appointment of Alfred G. Merriweather as Chief Financial Officer,
reporting to Gregory T. Went, Ph.D., Chairman and Chief Executive
Officer, and the retirement of William J. Dawson, its former Chief
Financial Officer. Mr. Merriweather will be responsible for leading
the company’s financial and administration organization including
its established teams in finance, accounting, SEC reporting,
treasury, investor relations and human resources.
“I am sincerely grateful to Bill Dawson for his
tremendous contribution to Adamas as CFO over the last three years,
during which time he built a strong and capable finance and
accounting organization as well as directly participated in raising
over $170 million in capital to fund the company’s growth. I
congratulate him on his retirement,” said Dr. Went. “Also, at this
important time of transition for the company from a development
organization to a full commercial entity, I am delighted to welcome
Alf Merriweather to Adamas with his extensive commercial and
financial experience.”
Mr. Merriweather joins Adamas as a New Drug
Application supporting ADS-5102 (amantadine) extended-release
capsules for the treatment of levodopa-induced dyskinesia in people
with Parkinson’s disease is under review by the U.S. Food and Drug
Administration (FDA) with a Prescription Drug User Fee Act (PDUFA)
action date of August 24, 2017. If approved, ADS-5102 will be the
first and only FDA-approved medicine indicated for the treatment of
levodopa-induced dyskinesia.
Mr. Merriweather has spent over 25 years in
executive leadership and senior financial positions with public and
private companies in the life sciences industry, including
Raindance Technologies, Inc. (acquired by Bio-Rad Laboratories,
Inc.), Verinata Health, Inc. (acquired by Illumina, Inc.), Celera
Corporation, Monogram Biosciences, Inc., and Laserscope. Mr.
Merriweather received a Bachelor’s degree from the University of
Cambridge in the United Kingdom.
“I am excited to join the Adamas team as the
company transforms itself into a full commercial organization, with
the potential approval and introduction of ADS-5102 in 2017,” said
Mr. Merriweather. “I have been impressed with Adamas’ proven
discovery platform. I look forward to contributing my skills and
experience to Adamas and its mission to improve the quality of life
for patients with chronic neurologic conditions.”
About Adamas Pharmaceuticals,
Inc.Adamas develops new medicines to improve the daily
lives of those affected by chronic neurologic disorders, including
Parkinson’s disease, multiple sclerosis, epilepsy, and Alzheimer’s
disease. Adamas has pioneered a platform to develop medicines for
chronic neurologic disorders based on an understanding of the
time-dependent biologic processes responsible for disease activity
and drug response. The company’s most advanced product candidate,
ADS-5102, is a high-dose amantadine, taken once-daily at bedtime,
in development for the treatment of levodopa-induced dyskinesia in
people with Parkinson’s disease and for the treatment of walking
impairment in people with multiple sclerosis. A New Drug
Application supporting ADS-5102 for the treatment of
levodopa-induced dyskinesia in people with Parkinson’s disease is
under review by the FDA with a PDUFA date of August 24, 2017.
Adamas is exploring other indications for further development of
ADS-5102. Adamas is also investigating ADS-4101 for the treatment
of partial onset seizures in patients with epilepsy. Additionally,
Adamas’ licensed assets, are currently marketed by Allergan under
the brand names NAMENDA XR® and NAMZARIC®, and Adamas is eligible
to receive royalties on sales of these medicines beginning in June
2018 and May 2020, respectively. For more information, please visit
www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz
Pharma GmbH & Co. KGaA.
Forward-looking Statements
Statements contained in this press release
regarding matters that may occur in the future are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including but not limited to, statements
contained in this press release regarding the potential approval of
ADS-5102 for the treatment of levodopa-induced dyskinesia in people
with Parkinson's disease and the potential clinical benefits of
ADS-5102. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. For a
description of risks and uncertainties that could cause actual
results to differ from those expressed in forward-looking
statements, including risks relating to Adamas' research, clinical,
development and commercial activities relating to ADS-5102 and
ADS-4101, the regulatory and competitive environment and Adamas'
business in general, see Adamas' Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on May 9, 2017.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release. Adamas undertakes no obligation to update any
forward-looking statement in this press release.
Contact:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
ir@adamaspharma.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2024 to May 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From May 2023 to May 2024